Explore

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.

GLP-1 Medications Transforming Health Beyond Weight Loss

GLP-1 Medications Transforming Health Beyond Weight Loss

GLP-1 Medications Transforming Health Beyond Weight Loss

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Allocates $250 Million Annually for Employee GLP-1 Drugs

Bank of America Allocates $250 Million Annually for Employee GLP-1 Drugs

Bank of America Allocates $250 Million Annually for Employee GLP-1 Drugs

Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales

Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales

Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...